Clinical TrialJun 25, 2026, 07:01 AM
Kymera Completes KT-621 BROADEN2 Enrollment Early; Data by Year-End
AI Summary
Kymera Therapeutics announced the early completion of enrollment for its global BROADEN2 Phase 2b trial of KT-621, a STAT6 degrader for moderate to severe atopic dermatitis. This achievement, nearly six months ahead of schedule, allows the company to accelerate the expected topline data readout to year-end 2026. Kymera also plans to initiate Phase 3 trials for KT-621 in AD by mid-2027, while the BREADTH Phase 2b asthma trial continues with data anticipated in late 2027.
Key Highlights
- BROADEN2 Phase 2b trial enrollment for KT-621 completed nearly six months ahead of schedule.
- Topline data readout for BROADEN2 trial accelerated to year-end 2026, from prior guidance of mid-2027.
- Phase 3 trials for KT-621 in atopic dermatitis (AD) are planned to initiate by mid-2027.
- BREADTH Phase 2b asthma trial for KT-621 is ongoing, with data expected in late 2027.
- BROADEN2 trial enrolled approximately 200 adult and adolescent patients with moderate to severe AD.
- KT-621 has received Fast Track designation from the FDA for AD and eosinophilic asthma.
Price Impact
More from KYMR